{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:38:49Z","timestamp":1790685529515,"version":"4.1.0"},"reference-count":98,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Instituto de Salud Carlos III (ISCIII) RICORS","award":["RICORS2040"],"award-info":[{"award-number":["RICORS2040"]}]},{"name":"European Union","award":["RICORS2040"],"award-info":[{"award-number":["RICORS2040"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Diabetes mellitus (DM) in kidney transplant recipients (KTR) is a risk factor for mortality, increases the risk of infections and, in the long term, can lead to graft loss due to diabetic kidney disease. A preventive approach applied to those on the waiting list could decrease the incidence of post-transplant DM (PTDM) by detecting those patients at risk, thus allowing strategies to minimize the probability of developing a New Onset Diabetes After Transplant (NODAT). On the other hand, modifications of immunosuppressive therapy may improve glucose control in patients with KTR. In recent years, two new classes of antidiabetic drugs and non-steroidal mineralocorticoid receptor antagonists have demonstrated cardiovascular and renal benefits in randomized clinical trials where the transplant population has not been represented. Because of the potential benefit expected in this population, the clinical use of glucagon-like peptide-1 receptor agonists (GLP-1RA), sodium-glucose cotransporter 2 inhibitors (SGLT2i) and finerenone is increasing in the kidney transplant setting. This review focuses on comprehensive pharmacological interventions in KTR with glucose metabolism disorders. In-depth knowledge in this area will allow prevention and identification of potential adverse effects or drug interactions in the clinical course of KTR with DM.<\/jats:p>","DOI":"10.3390\/jcm14041048","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T05:04:33Z","timestamp":1738904673000},"page":"1048","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Diabetes Mellitus in Kidney Transplant Recipients: New Horizons in Treatment"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1689-9383","authenticated-orcid":false,"given":"Maya","family":"Sanchez-Baya","sequence":"first","affiliation":[{"name":"Department of Nephrology, Hospital Universitario Germans Trias i Pujol, 08916 Barcelona, Spain"},{"name":"Redes de Investigaci\u00f3n Cooperativa Orientadas a Resultados en Salud (RICORS) 2040, 28029 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica","family":"Bolufer","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario Germans Trias i Pujol, 08916 Barcelona, Spain"},{"name":"Redes de Investigaci\u00f3n Cooperativa Orientadas a Resultados en Salud (RICORS) 2040, 28029 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6493-2374","authenticated-orcid":false,"given":"Federico","family":"V\u00e1zquez","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario Germans Trias i Pujol, 08916 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuria","family":"Alonso","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Nutrition, Hospital Universitario Germans Trias i Pujol, 08916 Barcelona, Spain"},{"name":"Germans Trias i Pujol Health Sciences Research Institute (IGTP), 08916 Badalona, Spain"},{"name":"Department of Medicine, Autonomous University of Barcelona (UAB), 08193 Barcelona, Spain"},{"name":"CIBER of Diabetes and Associated Metabolic Diseases, Instituto de Salud Carlos III, 08041 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabet","family":"Mass\u00f3","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario Germans Trias i Pujol, 08916 Barcelona, Spain"},{"name":"Redes de Investigaci\u00f3n Cooperativa Orientadas a Resultados en Salud (RICORS) 2040, 28029 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Paul","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario Germans Trias i Pujol, 08916 Barcelona, Spain"},{"name":"Redes de Investigaci\u00f3n Cooperativa Orientadas a Resultados en Salud (RICORS) 2040, 28029 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Coll-Brito","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario Germans Trias i Pujol, 08916 Barcelona, Spain"},{"name":"Redes de Investigaci\u00f3n Cooperativa Orientadas a Resultados en Salud (RICORS) 2040, 28029 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9081-5665","authenticated-orcid":false,"given":"Omar","family":"Taco","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario Germans Trias i Pujol, 08916 Barcelona, Spain"},{"name":"Redes de Investigaci\u00f3n Cooperativa Orientadas a Resultados en Salud (RICORS) 2040, 28029 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3521-6066","authenticated-orcid":false,"given":"Paula","family":"Anton-Pampols","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario Germans Trias i Pujol, 08916 Barcelona, Spain"},{"name":"Redes de Investigaci\u00f3n Cooperativa Orientadas a Resultados en Salud (RICORS) 2040, 28029 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosana","family":"Gelpi","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario Germans Trias i Pujol, 08916 Barcelona, Spain"},{"name":"Redes de Investigaci\u00f3n Cooperativa Orientadas a Resultados en Salud (RICORS) 2040, 28029 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iara","family":"DaSilva","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario Germans Trias i Pujol, 08916 Barcelona, Spain"},{"name":"Redes de Investigaci\u00f3n Cooperativa Orientadas a Resultados en Salud (RICORS) 2040, 28029 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngela","family":"Casas","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario Germans Trias i Pujol, 08916 Barcelona, Spain"},{"name":"Redes de Investigaci\u00f3n Cooperativa Orientadas a Resultados en Salud (RICORS) 2040, 28029 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosely","family":"Rodr\u00edguez","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario Germans Trias i Pujol, 08916 Barcelona, Spain"},{"name":"Redes de Investigaci\u00f3n Cooperativa Orientadas a Resultados en Salud (RICORS) 2040, 28029 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0033-4214","authenticated-orcid":false,"given":"Maria","family":"Molina","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario Germans Trias i Pujol, 08916 Barcelona, Spain"},{"name":"Redes de Investigaci\u00f3n Cooperativa Orientadas a Resultados en Salud (RICORS) 2040, 28029 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ca\u00f1as","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario Germans Trias i Pujol, 08916 Barcelona, Spain"},{"name":"Redes de Investigaci\u00f3n Cooperativa Orientadas a Resultados en Salud (RICORS) 2040, 28029 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Vila","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario Germans Trias i Pujol, 08916 Barcelona, Spain"},{"name":"Redes de Investigaci\u00f3n Cooperativa Orientadas a Resultados en Salud (RICORS) 2040, 28029 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Ara","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario Germans Trias i Pujol, 08916 Barcelona, Spain"},{"name":"Redes de Investigaci\u00f3n Cooperativa Orientadas a Resultados en Salud (RICORS) 2040, 28029 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3577-2273","authenticated-orcid":false,"given":"Jordi","family":"Bover","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hospital Universitario Germans Trias i Pujol, 08916 Barcelona, Spain"},{"name":"Redes de Investigaci\u00f3n Cooperativa Orientadas a Resultados en Salud (RICORS) 2040, 28029 Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,2,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1159\/000531334","article-title":"Inflammation on the Waiting List Is a Risk Factor for New-Onset Prediabetes and Post-Transplant Diabetes Mellitus: A Prospective Study","volume":"147","author":"Marrero","year":"2023","journal-title":"Nephron"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1111\/ajt.12850","article-title":"Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: Recommendations and future directions","volume":"14","author":"Sharif","year":"2014","journal-title":"Am. J. Transplant."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1093\/ndt\/gfad258","article-title":"International consensus on post-transplantation diabetes mellitus","volume":"39","author":"Sharif","year":"2024","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_4","unstructured":"Lorenzo, V., and L\u00f3pez G\u00f3mez, J.M. (2023). Diabetes Tras el Trasplante Renal, Elsevier. Available online: https:\/\/www.nefrologiaaldia.org\/298."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41574-018-0137-7","article-title":"Post-transplant diabetes mellitus in patients with solid organ transplants","volume":"15","author":"Jenssen","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2337\/dc23-1503","article-title":"Modifiable Lifestyle Factors, Genetic Risk, and Incident Peripheral Artery Disease Among Individuals with Type 2 Diabetes: A Prospective Study","volume":"47","author":"Zhu","year":"2024","journal-title":"Diabetes Care"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e2425106","DOI":"10.1001\/jamanetworkopen.2024.25106","article-title":"Type 2 Diabetes and Fracture Risk in Older Women","volume":"7","author":"Zoulakis","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1111\/jhn.13354","article-title":"Hypomagnesaemia, an independent risk factor for the development of post-transplant diabetes mellitus in liver and renal transplant recipients? A systematic review","volume":"37","author":"Chen","year":"2024","journal-title":"J. Hum. Nutr. Diet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e071934","DOI":"10.1136\/bmjopen-2023-071934","article-title":"Associations between human cytomegalovirus infection and type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"13","author":"Wang","year":"2023","journal-title":"BMJ Open"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.ekir.2018.07.009","article-title":"Randomized Controlled Trial Assessing the Impact of Tacrolimus Versus Cyclosporine on the Incidence of Posttransplant Diabetes Mellitus","volume":"3","author":"Torres","year":"2018","journal-title":"Kidney Int. Rep."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1097\/TP.0000000000001453","article-title":"Incidence of Posttransplantation Diabetes Mellitus in De Novo Kidney Transplant Recipients Receiving Prolonged-Release Tacrolimus-Based Immunosuppression With 2 Different Corticosteroid Minimization Strategies: ADVANCE, A Randomized Controlled Trial","volume":"101","author":"Mourad","year":"2017","journal-title":"Transplantation"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1034\/j.1600-6143.2003.00010.x","article-title":"Diabetes mellitus after kidney transplantation in the United States","volume":"3","author":"Kasiske","year":"2003","journal-title":"Am. J. Transplant."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Rodriguez-Rodriguez, A.E., Porrini, E., and Torres, A. (2021). Beta-Cell Dysfunction Induced by Tacrolimus: A Way to Explain Type 2 Diabetes?. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910311"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1210\/er.2015-1084","article-title":"Post-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes","volume":"37","author":"Shivaswamy","year":"2016","journal-title":"Endocr. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.mcna.2016.01.005","article-title":"Diabetes Care After Transplant: Definitions, Risk Factors, and Clinical Management","volume":"100","author":"Wallia","year":"2016","journal-title":"Med. Clin. N. Am."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"10352","DOI":"10.3389\/ti.2022.10352","article-title":"Posttransplantation Diabetes Mellitus Among Solid Organ Recipients in a Danish Cohort","volume":"35","author":"Hornum","year":"2022","journal-title":"Transpl. Int."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.34067\/KID.0000862021","article-title":"Post-transplant Diabetes Mellitus in Kidney Transplant Recipients: A Multicenter Study","volume":"2","author":"Malik","year":"2021","journal-title":"Kidney360"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2337\/dc23-1198","article-title":"Risk Factors for and Risk of Peripheral Artery Disease in Swedish Individuals With Type 2 Diabetes: A Nationwide Register-Based Study","volume":"47","author":"Avdic","year":"2024","journal-title":"Diabetes Care"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1097\/01.ASN.0000012382.97168.E0","article-title":"Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus","volume":"13","author":"Bloom","year":"2002","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0b013e3182497534","article-title":"Association of genetic polymorphisms of interleukins with new-onset diabetes after transplantation in renal transplantation","volume":"93","author":"Kim","year":"2012","journal-title":"Transplantation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/TP.0b013e31823f7f26","article-title":"Genetic polymorphisms of the transcription factor NFATc4 and development of new-onset diabetes after transplantation in Hispanic kidney transplant recipients","volume":"93","author":"Chen","year":"2012","journal-title":"Transplantation"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1097\/TP.0b013e3182a45283","article-title":"Association between 276G\/T adiponectin gene polymorphism and new-onset diabetes after kidney transplantation","volume":"96","author":"Nicoletto","year":"2013","journal-title":"Transplantation"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"100856","DOI":"10.1016\/j.trre.2024.100856","article-title":"Immunosuppressive drug combinations after kidney transplantation and post-transplant diabetes: A systematic review and meta-analysis","volume":"38","author":"Oliveras","year":"2024","journal-title":"Transplant. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Alajous, S., and Budhiraja, P. (2024). New-Onset Diabetes Mellitus after Kidney Transplantation. J. Clin. Med., 13.","DOI":"10.20944\/preprints202402.0314.v1"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1097\/01.ASN.0000145435.80005.1E","article-title":"Insulin resistance after renal transplantation: The effect of steroid dose reduction and withdrawal","volume":"15","author":"Midtvedt","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Sokooti, S., Szili-T\u00f6r\u00f6k, T., Heerspink, H.J.L., Dullaart, R.P.F., and Bakker, S.J.L. (2023). Indirect Insulin Resistance Indices and Their Cut-Off Values for the Prediction of Post-Transplantation Diabetes Mellitus in Kidney Transplant Recipients. J. Clin. Med., 12.","DOI":"10.3390\/jcm12237296"},{"key":"ref_27","first-page":"1","article-title":"Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients","volume":"4","author":"Webster","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Emerging Risk Factors Collaboration, Sarwar, N., Gao, P., Seshasai, S.R.K., Gobin, R., Kaptoge, S., Di Angelantonio, E., Ingelsson, E., Lawlor, D.A., and Selvin, E. (2010). Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. Lancet, 375, 2215\u20132222.","DOI":"10.1016\/S0140-6736(10)60484-9"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Chronic Kidney Disease Prognosis Consortium, Matsushita, K., van der Velde, M., Astor, B.C., Woodward, M., Levey, A.S., de Jong, P.E., Coresh, J., and Gansevoort, R.T. (2010). Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis. Lancet, 375, 2073\u20132081.","DOI":"10.1016\/S0140-6736(10)60674-5"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/TP.0b013e3181caeead","article-title":"Reduction in cardiovascular death after kidney transplantation","volume":"89","author":"Pilmore","year":"2010","journal-title":"Transplantation"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1097\/TP.0000000000003919","article-title":"Cardiometabolic and Kidney Protection in Kidney Transplant Recipients with Diabetes: Mechanisms, Clinical Applications, and Summary of Clinical Trials","volume":"106","author":"Sridhar","year":"2022","journal-title":"Transplantation"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2174\/157339911796397857","article-title":"Diabetes and cardiovascular disease following kidney transplantation","volume":"7","author":"Boerner","year":"2011","journal-title":"Curr. Diabetes Rev."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Rysz, J., Franczyk, B., Radek, M., Cia\u0142kowska-Rysz, A., and Gluba-Brz\u00f3zka, A. (2021). Diabetes and Cardiovascular Risk in Renal Transplant Patients. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22073422"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/j.1523-1755.2002.kid582.x","article-title":"Patient survival after renal transplantation: IV. Impact of post-transplant diabetes","volume":"62","author":"Cosio","year":"2002","journal-title":"Kidney Int."},{"key":"ref_36","first-page":"SS3","article-title":"New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003","volume":"75","author":"Davidson","year":"2003","journal-title":"Transplantation"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.2337\/dc12-2067","article-title":"Can new-onset diabetes after kidney transplant be prevented?","volume":"36","author":"Chakkera","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee 2 (2024). Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2024. Diabetes Care, 47, S20\u2013S42.","DOI":"10.2337\/dc24-S002"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1159\/000345143","article-title":"Effect of vascular comorbidities on survival of type 2 diabetes patients on renal replacement therapy","volume":"36","author":"Kervinen","year":"2012","journal-title":"Am. J. Nephrol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Kervinen, M.H., Lehto, S., Helve, J., Gr\u00f6nhagen-Riska, C., and Finne, P. (2018). Type 2 diabetic patients on renal replacement therapy: Probability to receive renal transplantation and survival after transplantation. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0201478"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"20543581231199011","DOI":"10.1177\/20543581231199011","article-title":"A Comparative Study on Graft and Overall Survival Rates Between Diabetic and Nondiabetic Kidney Transplant Patients Through Survival Analysis","volume":"10","author":"Hurtado","year":"2023","journal-title":"Can. J. Kidney Health"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1016\/j.transproceed.2012.11.013","article-title":"Kidney transplantation in type 2 diabetic patients: A matched survival analysis","volume":"45","author":"Rocha","year":"2013","journal-title":"Transplant. Proc."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S2213-8587(16)30317-5","article-title":"Long-term outcomes of kidney transplantation in people with type 2 diabetes: A population cohort study","volume":"5","author":"Lim","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/ki.2014.70","article-title":"Enhanced posttransplant management of patients with diabetes improves patient outcomes","volume":"86","author":"Keddis","year":"2014","journal-title":"Kidney Int."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s13098-021-00742-4","article-title":"Impact of diabetes mellitus developing after kidney transplantation on patient mortality and graft survival: A meta-analysis of adjusted data","volume":"13","author":"Lin","year":"2021","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s00125-014-3428-0","article-title":"Single-centre study of 628 adult, primary kidney transplant recipients showing no unfavourable effect of new-onset diabetes after transplant","volume":"58","author":"Gaynor","year":"2015","journal-title":"Diabetologia"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e14707","DOI":"10.1111\/dme.14707","article-title":"Comparing survival outcomes for kidney transplant recipients with pre-existing diabetes versus those who develop post-transplantation diabetes","volume":"39","author":"Hussain","year":"2022","journal-title":"Diabet. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13098-024-01547-x","article-title":"Evaluating the overall renal outcomes of sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with chronic kidney disease (CKD)","volume":"17","author":"Cao","year":"2025","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","article-title":"Canagliflozin and renal outcomes in type 2 diabetes: Results from the CANVAS Program randomised clinical trials","volume":"6","author":"Perkovic","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1093\/ndt\/gfae032","article-title":"How do SGLT2 inhibitors protect the kidney? A mediation analysis of the EMPA-REG OUTCOME trial","volume":"39","author":"Wanner","year":"2024","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1681\/ASN.2020050723","article-title":"Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A PostHoc Analysis from the CREDENCE Trial","volume":"31","author":"Oshima","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","article-title":"Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: A prespecified analysis from the DAPA-CKD trial","volume":"9","author":"Wheeler","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"The EMPA-KIDNEY Collaborative Group, Herrington, W.G., Staplin, N., Wanner, C., Green, J.B., Hauske, S.J., Emberson, J.R., Preiss, D., Judge, P., and Mayne, K.J. (2023). Empagliflozin in Patients with Chronic Kidney Disease. N. Engl. J. Med., 388, 117\u2013127.","DOI":"10.1056\/NEJMoa2204233"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2337\/dc19-0093","article-title":"Efficacy and Safety of Empagliflozin in Renal Transplant Recipients With Posttransplant Diabetes Mellitus","volume":"42","author":"Halden","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.2337\/dc17-0237","article-title":"Use of Canagliflozin in Kidney Transplant Recipients for the Treatment of Type 2 Diabetes: A Case Series","volume":"40","author":"Rajasekeran","year":"2017","journal-title":"Diabetes Care"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1016\/j.transproceed.2019.05.023","article-title":"Use of Empagliflozin in Recipients of Kidney Transplant: A Report of 8 Cases","volume":"51","author":"Attallah","year":"2019","journal-title":"Transplant. Proc."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e00185","DOI":"10.1002\/edm2.185","article-title":"Early initiation of sodium-glucose linked transporter inhibitors (SGLT-2i) and associated metabolic and electrolyte outcomes in diabetic kidney transplant recipients","volume":"4","author":"Song","year":"2021","journal-title":"Endocrinol. Diabetes Metab."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e14718","DOI":"10.1111\/ctr.14718","article-title":"Sodium-glucose cotransporter 2 inhibitors for treatment of diabetes mellitus after kidney transplantation","volume":"36","author":"Lemke","year":"2022","journal-title":"Clin. Transplant."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4103\/ijn.IJN_2_18","article-title":"Efficacy and Safety of Canagliflozin in Kidney Transplant Patients","volume":"29","author":"Shah","year":"2019","journal-title":"Indian J. Nephrol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/ajt.15223","article-title":"Empagliflozin in posttransplantation diabetes mellitus: A prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety","volume":"19","author":"Schwaiger","year":"2019","journal-title":"Am. J. Transplant."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1159\/000501854","article-title":"Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus","volume":"44","author":"Mahling","year":"2019","journal-title":"Kidney Blood Press. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/ckj\/sfad007","article-title":"Sodium-glucose cotransporter-2 inhibitor therapy in kidney transplant patients with type 2 or post-transplant diabetes: An observational multicentre study","volume":"16","year":"2023","journal-title":"Clin. Kidney J."},{"key":"ref_63","unstructured":"(2025, January 26). CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients (CREST-KT). NCT04906213, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04906213."},{"key":"ref_64","unstructured":"(2025, January 26). Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients (INFINITI2019). NCT04965935, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04965935?term=INFINITI2019&rank=1."},{"key":"ref_65","unstructured":"(2025, January 26). The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant Recipients (HALLMARK). NCT05938712, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05938712."},{"key":"ref_66","unstructured":"(2025, January 26). Can Dapagliflozin Preserve Structure and Function in Transplanted Kidneys? NCT05788276, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05788276."},{"key":"ref_67","unstructured":"(2025, January 26). Effect of Adding Dapagliflozin to Allograft Dysfunction of Renal Transplanted Patients, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04743453."},{"key":"ref_68","unstructured":"(2025, January 26). Empagliflozin Treatment in Kidney Transplant Recipients (SEKTR). NCT06013865, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06013865."},{"key":"ref_69","unstructured":"(2025, January 26). Effects of Empagliflozin in Reducing Oxidative Stress After Kidney Transplantation. ClinicalTrials.gov ID NCT04918407, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04918407?term=transplant%20kidney%20SGLT2&page=5&rank=41."},{"key":"ref_70","unstructured":"(2025, January 26). Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes, Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus (EmLinaRenal). ClinicalTrials.gov ID NCT06095492, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06095492?term=emlina%20renal&rank=2."},{"key":"ref_71","unstructured":"(2025, January 26). A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD. The RENAL LIFECYCLE Trial. NCT05374291, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05374291?cond=RENAL%20LIFECYCLE%20Trial%20%20&rank=1."},{"key":"ref_72","unstructured":"(2025, January 26). SGLT2i in Diabetic Patients with Renal Transplantation. ClinicalTrials.gov ID NCT06731231, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06731231?term=transplant%20kidney%20SGLT2&rank=10."},{"key":"ref_73","unstructured":"(2025, January 26). Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients. ClinicalTrials.gov ID NCT06140537, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06140537?term=transplant%20kidney%20SGLT2&page=2&rank=13."},{"key":"ref_74","unstructured":"(2025, January 26). Dapagliflozin on Renal Morphology and Renal Perfusion in Patients One Year After Kidney Transplantation. ClinicalTrials.gov ID NCT06560801, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06560801?term=transplant%20kidney%20SGLT2&page=5&rank=42."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: A systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","article-title":"Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER","volume":"145","author":"Shaman","year":"2022","journal-title":"Circulation"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"sfae018","DOI":"10.1093\/ckj\/sfae018","article-title":"Safety and efficacy of glucagon-like peptide-1 receptor agonists among kidney transplant recipients: A systematic review and meta-analysis","volume":"17","author":"Krisanapan","year":"2024","journal-title":"Clin. Kidney J."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Bellos, I., Lagiou, P., Benetou, V., and Marinaki, S. (2024). Safety and Efficacy of Sodium-Glucose Transport Protein 2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists in Diabetic Kidney Transplant Recipients: Synthesis of Evidence. J. Clin. Med., 13.","DOI":"10.3390\/jcm13206181"},{"key":"ref_82","first-page":"100343","article-title":"Safety and efficacy of semaglutide in post kidney transplant patients with type 2 diabetes or Post-Transplant diabetes","volume":"36","author":"Mahzari","year":"2024","journal-title":"J. Clin. Transl. Endocrinol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"5931","DOI":"10.1111\/dom.15967","article-title":"Semaglutide in patients with kidney failure and obesity undergoing dialysis and wishing to be transplanted: A prospective, observational, open-label study","volume":"26","author":"Vanek","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"814","DOI":"10.4158\/EP14569.RA","article-title":"THE RATIONALE FOR USE OF INCRETINS IN THE MANAGEMENT OF NEW ONSET DIABETES AFTER TRANSPLANTATION (NODAT)","volume":"21","author":"Sadhu","year":"2015","journal-title":"Endocr. Pract."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e130770","DOI":"10.1172\/jci.insight.130770","article-title":"Tacrolimus- and sirolimus-induced human \u03b2 cell dysfunction is reversible and preventable","volume":"5","author":"Dai","year":"2020","journal-title":"JCI Insight"},{"key":"ref_86","unstructured":"(2025, January 26). Semaglutide Treatment for Hyperglycaemia After Renal Transplantation (Sema-RTx). ClinicalTrials.gov ID NCT05702931, Available online: https:\/\/clinicaltrials.gov\/study\/NCT05702931."},{"key":"ref_87","unstructured":"(2025, January 26). Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2. ClinicalTrials.gov ID NCT06396416, Available online: https:\/\/clinicaltrials.gov\/study\/NCT06396416."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.nefro.2022.09.002","article-title":"Finerenona: Completando el abordaje del paciente con enfermedad renal y diabetes","volume":"43","author":"Facila","year":"2023","journal-title":"Nefrologia"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.2215\/CJN.13121215","article-title":"Inflammation and Progression of CKD: The CRIC Study","volume":"11","author":"Amdur","year":"2016","journal-title":"Clin J. Am. Soc. Nephrol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: The FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease","volume":"102","author":"Rossing","year":"2022","journal-title":"Kidney Int."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1093\/ndt\/gfy065","article-title":"Mineralocorticoid receptor antagonists in kidney transplantation: Time to consider?","volume":"33","author":"Girerd","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_95","unstructured":"(2025, January 26). The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study. NCT06059664. Available online: https:\/\/ctv.veeva.com\/study\/the-effect-of-finerenone-in-kidney-transplantion-recipients-the-effektor-study."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Valencia-Morales, N.D., Rodr\u00edguez-Cubillo, B., Loayza-L\u00f3pez, R.K., Moreno de la Higuera, M.\u00c1., and S\u00e1nchez-Fructuoso, A.I. (2023). Novel Drugs for the Management of Diabetes Kidney Transplant Patients: A Literature Review. Life, 13.","DOI":"10.3390\/life13061265"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Lim, S.W., Jin, L., Jin, J., and Yang, C.W. (2016). Effect of Exendin-4 on Autophagy Clearance in Beta Cell of Rats with Tacrolimus-induced Diabetes Mellitus. Sci. Rep., 6.","DOI":"10.1038\/srep29921"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Rudzki, G., Knop-Chody\u0142a, K., Piasecka, Z., Kochanowska-Mazurek, A., G\u0142az, A., Weso\u0142ek-Bielaska, E., and Wo\u017aniak, M. (2024). Managing Post-Transplant Diabetes Mellitus after Kidney Transplantation: Challenges and Advances in Treatment. Pharmaceuticals, 17.","DOI":"10.3390\/ph17080987"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/4\/1048\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:28:38Z","timestamp":1760027318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/4\/1048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":98,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["jcm14041048"],"URL":"https:\/\/doi.org\/10.3390\/jcm14041048","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]}}}